Minako Saito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minako Saito has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Taro Ishimori
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan
9 shared publications - Akihisa Mitani
Department of Respiratory Medicine, Graduate School of Medicine The University of Tokyo Tokyo Japan
8 shared publications - Hideaki Isago
The University of Tokyo
8 shared publications - Takahide Nagase
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
8 shared publications - Taisuke Jo
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-0033, Japan
7 shared publications - Hiroyuki Tamiya
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan
6 shared publications
Latest Publications
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 329 (2) , L200-L213
Sirtuin 3 deficiency exacerbates emphysema and lung inflammation in a murine model of chronic obstructive pulmonary disease
Our study is the first to elucidate the protective role of SIRT3 in the pathogenesis of COPD by modulating inflammatory responses and apoptosis. We have demonstrated that SIRT3 knockout mice spontaneously develop emphysema, and SIRT3 overexpression reduced elastase and LPS-induced emphysematous changes. In vitro studies have shown that SIRT3 deficiency leads to increased inflammation, oxidative stress, and apoptosis in airway and alveolar epithelium, contributing to the formation and exacerbation of emphysema.
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 329 (2) , L200-L213
Sirtuin 3 deficiency exacerbates emphysema and lung inflammation in a murine model of chronic obstructive pulmonary disease
Our study is the first to elucidate the protective role of SIRT3 in the pathogenesis of COPD by modulating inflammatory responses and apoptosis. We have demonstrated that SIRT3 knockout mice spontaneously develop emphysema, and SIRT3 overexpression reduced elastase and LPS-induced emphysematous changes. In vitro studies have shown that SIRT3 deficiency leads to increased inflammation, oxidative stress, and apoptosis in airway and alveolar epithelium, contributing to the formation and exacerbation of emphysema.
- Open Access
- 19 November 2021
- Published by Wiley in Respirology
- Vol. 26 (S3) , 102
P1‐70: Yokukansan and in‐hospital mortality in patients with pneumonia
- 19 November 2021
- Published by Wiley in Respirology
- Vol. 26 (S3) , 102
Open AccessP1‐70: Yokukansan and in‐hospital mortality in patients with pneumonia
- Open Access
- 19 November 2021
- Published by Wiley in Respirology
- Vol. 26 (S3) , 102
P1‐71: Breath‐actuated inhalation therapy: Survey of physicians' perception (INTROSPECT) in Nepal
- 19 November 2021
- Published by Wiley in Respirology
- Vol. 26 (S3) , 102
Open AccessP1‐71: Breath‐actuated inhalation therapy: Survey of physicians' perception (INTROSPECT) in Nepal
- Open Access
- 19 November 2021
- Published by Wiley in Respirology
- Vol. 26 (S3) , 102-103
P1‐72: A case of lung intravascular large B cell lymphoma developed with acute respiratory failure: Usefulness of corticosteroid rescue prior to define diagnosis
- 19 November 2021
- Published by Wiley in Respirology
- Vol. 26 (S3) , 102-103
Open AccessP1‐72: A case of lung intravascular large B cell lymphoma developed with acute respiratory failure: Usefulness of corticosteroid rescue prior to define diagnosis
- Open Access
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A1201
mTOR Enhances Fibrosis in Lung by Promoting Epithelial Cells Vulnerability and Epithelial Mesenchymal Transition
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A1201
Open AccessmTOR Enhances Fibrosis in Lung by Promoting Epithelial Cells Vulnerability and Epithelial Mesenchymal Transition
- Open Access
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A2332
Measurement of Chest Wall Motion by High-Speed Whole-Field Three-Dimensional Motion Capture
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A2332
Open AccessMeasurement of Chest Wall Motion by High-Speed Whole-Field Three-Dimensional Motion Capture
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4052
Sirtuin3 reduces acute lung inflammation and emphysematous aggravation in COPD exacerbation mouse model
Backgrounds: Chronic obstructive pulmonary disease (COPD) is a pulmonary disease with permanent airflow obstruction and emphysema, and acute exacerbation of COPD is often induced by infection often resulting in a poor prognosis. Reactive oxygen species (ROS), producted in mitochondria, has been reported to accelerate the establishment of COPD. Sirtuin3(SIRT3) is the mitochondrial NAD(+)-dependent deacetylase, which regulates ROS formation and proinflammatory responses. It is also reported to be related with lifespan longevity. Aims: The aim of our study was to investigate the role of SIRT3 in COPD exacerbation mouse model generated by porcine pancreatic elastase(PPE) and lipopolysaccharide(LPS). Methods: PPE followed by LPS was administered intratracheally to wild-type (WT) or SIRT3 overexpressing transgenic(SIRT3 OE), SIRT3 knockout (SIRT3 KO) male mice. The next day (early phase) and 4weeks later (late phase) after LPS administration, BALF analysis and lung function test was conducted. Results: In early phase, the BALF cell count of SIRT3 OE mice was significantly increased compared to control WT mice, whereas that of SIRT3 KO mice was significantly decreased. In late phase, the lung compliance was increased in SIRT3 OE mice compared to WT mice, and decreased in SIRT3 KO mice. Conclusions: Our study showed that SIRT3 surpressed acute lung injury and emphysematous worsening in COPD model mice. SIRT3 would serve as a new therapeutic target to COPD and COPD exacerbation.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4052
Sirtuin3 reduces acute lung inflammation and emphysematous aggravation in COPD exacerbation mouse model
Backgrounds: Chronic obstructive pulmonary disease (COPD) is a pulmonary disease with permanent airflow obstruction and emphysema, and acute exacerbation of COPD is often induced by infection often resulting in a poor prognosis. Reactive oxygen species (ROS), producted in mitochondria, has been reported to accelerate the establishment of COPD. Sirtuin3(SIRT3) is the mitochondrial NAD(+)-dependent deacetylase, which regulates ROS formation and proinflammatory responses. It is also reported to be related with lifespan longevity. Aims: The aim of our study was to investigate the role of SIRT3 in COPD exacerbation mouse model generated by porcine pancreatic elastase(PPE) and lipopolysaccharide(LPS). Methods: PPE followed by LPS was administered intratracheally to wild-type (WT) or SIRT3 overexpressing transgenic(SIRT3 OE), SIRT3 knockout (SIRT3 KO) male mice. The next day (early phase) and 4weeks later (late phase) after LPS administration, BALF analysis and lung function test was conducted. Results: In early phase, the BALF cell count of SIRT3 OE mice was significantly increased compared to control WT mice, whereas that of SIRT3 KO mice was significantly decreased. In late phase, the lung compliance was increased in SIRT3 OE mice compared to WT mice, and decreased in SIRT3 KO mice. Conclusions: Our study showed that SIRT3 surpressed acute lung injury and emphysematous worsening in COPD model mice. SIRT3 would serve as a new therapeutic target to COPD and COPD exacerbation.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4214
Japanese herbal medicine Hochu-ekki-to (TJ-41) attenuates lung inflammation in lung emphysema
Background: Chronic Obstructive Pulmonary Disease (COPD) is a systemic inflammatory disease, and often causes weight loss, which is considered as a poor prognostic factor. A Japanese herbal medicine, Hochu-ekki-to (TJ-41), was reported to prevent weight loss in a small study of COPD patients, while its biological mechanism is unknown. Objective: The objective of our study was to evaluate the role of TJ-41 using mouse lung emphysema model, and to investigate its biological mechanism in vivo and in vitro. Methods: We used lung epithelial specific Taz conditional knockout mice (Taz CKO mice) as emphysema model mice, and fed a diet containing 2% TJ-41 or a control diet for 12 weeks. During administration, body weights were measured. After seeding, Taz CKO mice and control mice were subjected to BALF analysis, and lung mRNA expressions of inflammatory cytokines were analysed by RT-PCR. Results: After treatment, Taz CKO mice showed higher body weights in TJ-41 group compared to control diet group. BALF analysis showed decreased number of inflammatory cells in TJ-41 group, and among inflammatory cytokines, IL-8 expression was also significantly decreased. Conclusion: Our results suggest the possibility that TJ-41 attenuates lung inflammation, and thereby prevents weight loss of COPD patients. Among inflammatory cytokines, IL-8 is downregulated by administration of TJ-41, which coincided with decreased number of inflammatory cells in BALF in TJ-41 group. Our study sheds light on the biological mechanism of TJ-41 in lung emphysema, and suggests its potential for anti-inflammatory therapy for COPD patients.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4214
Japanese herbal medicine Hochu-ekki-to (TJ-41) attenuates lung inflammation in lung emphysema
Background: Chronic Obstructive Pulmonary Disease (COPD) is a systemic inflammatory disease, and often causes weight loss, which is considered as a poor prognostic factor. A Japanese herbal medicine, Hochu-ekki-to (TJ-41), was reported to prevent weight loss in a small study of COPD patients, while its biological mechanism is unknown. Objective: The objective of our study was to evaluate the role of TJ-41 using mouse lung emphysema model, and to investigate its biological mechanism in vivo and in vitro. Methods: We used lung epithelial specific Taz conditional knockout mice (Taz CKO mice) as emphysema model mice, and fed a diet containing 2% TJ-41 or a control diet for 12 weeks. During administration, body weights were measured. After seeding, Taz CKO mice and control mice were subjected to BALF analysis, and lung mRNA expressions of inflammatory cytokines were analysed by RT-PCR. Results: After treatment, Taz CKO mice showed higher body weights in TJ-41 group compared to control diet group. BALF analysis showed decreased number of inflammatory cells in TJ-41 group, and among inflammatory cytokines, IL-8 expression was also significantly decreased. Conclusion: Our results suggest the possibility that TJ-41 attenuates lung inflammation, and thereby prevents weight loss of COPD patients. Among inflammatory cytokines, IL-8 is downregulated by administration of TJ-41, which coincided with decreased number of inflammatory cells in BALF in TJ-41 group. Our study sheds light on the biological mechanism of TJ-41 in lung emphysema, and suggests its potential for anti-inflammatory therapy for COPD patients.
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , PA773
The effect preoperative intervention with long-acting bronchodilator for untreated patients with obstructive lung disease
Background and Aim: Untreated obstructive lung diseases (OLD) including COPD, BA are incidentally discovered in preoperative patients who has been evaluated by pulmonary function testing. Airflow limitation in OLD is a major risk for postoperative pulmonary complications (PPC) and inhaled long-acting bronchodilators (ILB) such as LAMA and LABA are key drugs for the management of OLD, especially for COPD. However, the effect of medication with ILB just before surgery in untreated OLD patients remain elusive. The aim of this study was to evaluate whether intervention with ILB just before surgery provides therapeutic benefit in those patients. Method: We retrospectively analyzed patients who were referred to the Department of Respiratory Medicine for untreated OLD with airflow limitation (FEV1/FVC3days) after surgery was assessed as an outcome for PPC. Patients treated with ILB and untreated control patients were matched for propensity scores (PS) and were statistically compared. Result: A total of 614 patients were analyzed. The number of patients with COPD, BA, and ACO were 541, 45, and 28 respectively. PPC was developed in 180 patients (29.1%). ILB was administered in 132 patients. In 98 pairs of PS matched patients, the incidence of PPC was not significantly different between the ILB group and the control group (33.6 vs 30.0% p=0.54). Conclusion: Preoperative short term ILB therapy in patients with OLD may not reduce PPC.
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , PA773
The effect preoperative intervention with long-acting bronchodilator for untreated patients with obstructive lung disease
Background and Aim: Untreated obstructive lung diseases (OLD) including COPD, BA are incidentally discovered in preoperative patients who has been evaluated by pulmonary function testing. Airflow limitation in OLD is a major risk for postoperative pulmonary complications (PPC) and inhaled long-acting bronchodilators (ILB) such as LAMA and LABA are key drugs for the management of OLD, especially for COPD. However, the effect of medication with ILB just before surgery in untreated OLD patients remain elusive. The aim of this study was to evaluate whether intervention with ILB just before surgery provides therapeutic benefit in those patients. Method: We retrospectively analyzed patients who were referred to the Department of Respiratory Medicine for untreated OLD with airflow limitation (FEV1/FVC3days) after surgery was assessed as an outcome for PPC. Patients treated with ILB and untreated control patients were matched for propensity scores (PS) and were statistically compared. Result: A total of 614 patients were analyzed. The number of patients with COPD, BA, and ACO were 541, 45, and 28 respectively. PPC was developed in 180 patients (29.1%). ILB was administered in 132 patients. In 98 pairs of PS matched patients, the incidence of PPC was not significantly different between the ILB group and the control group (33.6 vs 30.0% p=0.54). Conclusion: Preoperative short term ILB therapy in patients with OLD may not reduce PPC.
- Open Access
- 1 January 2017
- Published by Longdom Group in Journal of Cancer Research and Immuno-Oncology
- Vol. 03 (01)
Changes in Knowledge Levels through Lectures on Radiotherapy to Nursing Students in Japan
- 1 January 2017
- Published by Longdom Group in Journal of Cancer Research and Immuno-Oncology
- Vol. 03 (01)
Open AccessChanges in Knowledge Levels through Lectures on Radiotherapy to Nursing Students in Japan